When first-line treatment isn’t enough, what next? Emma and Mark explore the role of additional anti-epileptic medications such as potassium bromide, levetiracetam and more. With an evidence-based view of expectations and side effects, they also dive into complementary approaches. From MCT diets and CBD oil to the emerging relevance of the gut-brain axis, this episode helps clinicians navigate a crowded therapeutic space with evidence, empathy and nuance.
Podden och tillhörande omslagsbild på den här sidan tillhör
Dômes Pharma UK. Innehållet i podden är skapat av Dômes Pharma UK och inte av,
eller tillsammans med, Poddtoppen.
